What's New?

Press and Publications

Leukocyte Surface Biomarkers in Sporadic AD

The research supporting our groundbreaking technology for early detection as published in the Alzheimer's & Dementia Journal.

NeuroQuest and AIBL Collaborative Study

As published in BioSpace, the article discusses how using specific biomarkers for Alzheimer’s could lead to a blood-based screening Tool.

SC Launch Inc. Announces Investment in NeuroQuest

SC Launch Inc., the investment affiliate of the South Carolina Research Authority (SCRA), has invested $250,000 in NeuroQuest.

Our CEO, Jason Maxwell, on the South Carolina Public Radio.

SC Business Review focuses on news from South Carolina's business community and promotes local small businesses. Thank you for having us!

AAIC

We were excited to attend AAIC 2025 (Alzheimer's Association International Conference), where the leading global medical and scientific dementia researcher community comes together every year "to learn about the latest research, products, and solutions available in the treatment of Alzheimer’s and related dementias."

We had the opportunity to discuss our progress with industry experts, exchange theories, breakthroughs, and practices. We attended fascinating lectures and gained many valuable insights. We can't wait to apply everything while working on NeuroScreen®.

AAIC took place July 27-31, 2025, in Toronto, Canada.

What is the AAIC?

Clinical Validation

We recently completed our 2024 clinical study at Vikor Scientific LLC, a CLIA-certified lab in Charleston, SC. The next step is completing a biostatistical analysis, for which we are collaborating with Pentara Corporation and should have the results by the end of 2025.

What is CLIA testing?

As we wrap up the 2024 study analysis, we are already gearing up for our Fall 2025 clinical validation study. This study will use 2,500 blood samples provided to us by the groundbreaking AHEAD Study, which tests "whether an investigational treatment can slow or stop the earliest brain changes due to Alzheimer’s disease in people with a higher risk of developing the disease later in life."

The validation process is essential to provide data for the FDA application, NIH grants, and to start commercializing our test.

Take a sneak peek into our lab - Fall 2024 Study

FDA Application

We are working on a Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). Once the clinical validation process is completed, we will submit a 510(k) SaMD application to the FDA and expect a response regarding the designation in the following months.

What is the Breakthrough Devices Program?

Funding

We will close the current funding round once we raise enough capital or non-dilutive funding. We have recently secured a $250,000 investment from SC Launch, Inc., the South Carolina Research Authority (SCRA) investment affiliate.

We are also aiming to be part of Johns Hopkins' BioCard Study, which could qualify us for a supplemental NIH (National Institutes of Health) grant to include us in their long-term research. The process is expected to take approximately 4-6 months.

About SC Launch, Inc.